Clinical trial
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed…
NCT00124657 · St. Jude Children's Research Hospital, Other · Completed
Key facts
| NCT number | NCT00124657 |
|---|---|
| Title | Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma |
| Official title | A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) During and After Radiotherapy in the Treatment of Patients With Newly Diagnosed High Grade Glioma and Unfavorable Low-Grade Glioma |
| Lead sponsor | St. Jude Children's Research Hospital, Other |
| Collaborators | Rady Children's Hospital, San Diego Duke University |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | Erlotinib hydrochloride |
| Enrollment | 62 |
| Start date | Mar 1, 2005 |
| Primary completion | Jul 1, 2012 |
| Completion | Sep 1, 2014 |
| First posted | Jul 28, 2005 |
| Last update posted | Dec 4, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: